TG4.F · Oxurion NV

-

Please sign in to comment on TG4.F

1 Comment

Admin

4 years ago

Oxurion NV is currently in a long term downtrend where the price is trading 5.7% below its 200 day moving average.

From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 28.0.

Oxurion NV's total revenue sank by 0.0% to $1M since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-9M since the same quarter in the previous year.

Finally, its free cash flow grew by 8.0% to $-6M since the same quarter in the previous year.

Based on the above factors, Oxurion NV gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
Sector	Healthcare
Industry	Biotechnology
ISIN	BE0003846632

Target Price	None
Beta	0.58
Market Cap	267
PE Ratio	None
Dividend Yield	None

ABOUT

Oxurion NV

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

TG4.F · Oxurion NV

-

Oxurion NV

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Oxurion NV using a moving average strategy